Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 61186372NSC2002 | Other Identifier | Janssen Research & Development, LLC | |
| 2022-000526-21 | EudraCT Number | ||
| 2023-505065-91-00 | Registry Identifier | EUCT number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to assess the anti-tumor activity and safety of amivantamab which will be administered as a co-formulation with recombinant human hyaluronidase PH20 (rHuPH20) (subcutaneous co-formulation [SC-CF]) in combination treatment (all cohorts except Cohort 4) and to characterize the safety of amivantamab SC-CF (Cohort 4).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cohort 1(Exon19del/Exon21 L858R NSCLC, 1L, Previously Untreated): Amivantamab (Q2W) + Lazertinib | Experimental | Participants with treatment-naive locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) exon 19 deletion (exon19del) or exon 21 leucine 858 to arginine substitution (exon 21 L858R) mutation, will receive amivantamab SC-CF injection, 1600 milligrams (mg) or 2240 mg if body weight is greater than or equal to (>=) 80 kilograms (kg), on Cycle 1 Days 1, 8, 15, and 22 and on Days 1 and 15 of each subsequent 28-day cycle, starting with Cycle 2, along with lazertinib 240 mg orally once daily. Eligible participants will be given an option to enter long-term extension (LTE) phase and may continue to receive access to study treatment(s) within the study by transferring to the Drug Access (DA)-LTE Phase. |
|
| Cohort 2(Exon20 NSCLC,1L, Previously Untreated): Amivantamab (Q3W) + Chemotherapy | Experimental | Participants with treatment-naive locally advanced or metastatic NSCLC harboring an EGFR exon20ins mutation will receive Amivantamab SC-CF injection 1600 mg or 2240 mg if body weight is >=80 kg on Cycle 1 Day 1, 2400 mg or 3360 mg if body weight is >=80 kg on Cycle 1 Day 8 and 15 and on Day 1 of each subsequent 21-day cycle, starting with Cycle 2 along with pemetrexed 500 milligrams per meter square (mg/m^2) as intravenous (IV) infusion (with vitamin supplementation) on Day 1 of each 21-day cycle and IV infusion carboplatin area under the concentration-time curve 5 milligrams per milliliters (mg/mL) per minute (AUC 5) maximum 750 mg on Day 1 of each 21-day cycle, for up to 4 cycles. Eligible participants will be given an option to enter LTE phase and may continue to receive access to study treatment(s) within the study by transferring to the DA-LTE Phase. |
|
| Cohort 3(Exon19del/Exon21 L858R NSCLC,2L,Post Osimertinib):Amivantamab(Q3W)+Lazertinib+Chemotherapy |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Amivantamab | Drug | Amivantamab will be administered subcutaneously by manual injection. |
|
| Measure | Description | Time Frame |
|---|---|---|
| All Cohorts Except Cohort 4: Objective Response Rate (ORR) Based on Investigator Assessment (INV) | ORR based on INV will be reported. ORR is defined as the percentage of participants who achieve a complete response (CR) or partial response (PR), based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, as determined by investigator. | Up to 1 year 6 months |
| Cohort 4: Number of Participants with Adverse Events (AEs) | An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. | Up to approximately 4 years and 9 months |
| Cohort 4: Number of Participants with AEs by Severity | An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. Severity of AEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event. | Up to approximately 4 years and 9 months |
| Cohort 4: Number of Participants with Abnormalities in Clinical Laboratory Values | Number of participants with abnormalities in clinical laboratory values (which includes serum chemistry, hematology, coagulation, urinalysis, and serology) will be reported. | Up to approximately 4 years and 9 months |
| Cohort 4: Number of Participants with Abnormalities in Clinical Laboratory Values by Severity | Number of participants with laboratory values abnormalities which includes serum chemistry, hematology, coagulation, urinalysis, and serology) by severity will be reported. Severity of laboratory values abnormalities will be graded according to the NCI-CTCAE version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event. |
| Measure | Description | Time Frame |
|---|---|---|
| All Cohorts Except Cohort 4: Number of Participants with AEs | An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. | Up to 1 year 6 months |
| All Cohorts Except Cohort 4: Number of Participants with AEs by Severity |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Study Contact | Contact | 844-434-4210 | Participate-In-This-Study1@its.jnj.com |
| Name | Affiliation | Role |
|---|---|---|
| Janssen Research & Development, LLC Clinical Trial | Janssen Research & Development, LLC | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of California at San Diego | Recruiting | La Jolla | California | 92093 | United States | |
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Experimental |
Participants with locally advanced or metastatic NSCLC harboring an EGFR exon19del or exon 21 L858R mutation who have experienced disease progression on or after treatment with a third-generation EGFR TKI (osimertinib), will receive amivantamab SC-CF injection 1600 mg or 2240 mg if body weight is >=80 kg on Cycle 1 Day 1, 2400 mg or 3360 mg if body weight is >=80 kg on Cycle 1 Day 8 and 15 and on Day 1 of each subsequent 21-day cycle starting with Cycle 2; in combination with IV infusion carboplatin area under the concentration-time curve 5 mg/mL per minute (AUC 5) maximum 750 mg on Day 1 of each 21-day cycle, for up to 4 cycles; and pemetrexed 500 mg/m^2 as an IV infusion (with vitamin supplementation) on Day 1 of each 21-day until disease progression. Lazertinib 240 mg orally once daily starting Cycle 5 Day 1 when carboplatin is complete or sooner if carboplatin discontinued earlier than Cycle 4. Eligible participants will be given an option to enter LTE phase and DA-LTE Phase. |
|
| Cohort 3b(Exon19del/Exon21 L858R NSCLC, 2L, Post Osimertinib): Amivantamab (Q3W)+Chemotherapy | Experimental | Participants with locally advanced or metastatic NSCLC harboring an EGFR exon19del or exon 21 L858R mutation who have experienced disease progression on or after treatment with a third-generation EGFR TKI (osimertinib), will receive amivantamab SC-CF injection 1600 mg or 2240 mg if body weight is >=80 kg on Cycle 1 Day 1, 2400 mg or 3360 mg if body weight is >=80 kg on Cycle 1 Day 8 and 15 and on Day 1 of each subsequent 21-day cycle starting with Cycle 2; in combination with IV infusion carboplatin area under the concentration-time curve 5 mg/mL per minute (AUC 5) maximum 750 mg on Day 1 of each 21-day cycle, for up to 4 cycles; and pemetrexed 500 mg/m^2 as an IV infusion (with vitamin supplementation) on Day 1 of each 21-day until disease progression. Eligible participants will be given an option to enter LTE phase and may continue to receive access to study treatment(s) within the study by transferring to the DA-LTE Phase. |
|
| Cohort 4(Previously Treated with Amivantamab IV): Switch from Amivantamab IV to SC-CF (Q2W) | Experimental | Participants who were previously on amivantamab IV once every 2 weeks (Q2W) regimen as part of standard of care, for at least 8 weeks, either as monotherapy or combination with lazertinib, will receive amivantamab SC-CF injection 1600 mg and 2240 mg if body weight is greater than or equal to 80 kg. Participants who continue to benefit from study treatments, as determined by their investigator, may shift to the drug access (DA)-LTE phase. |
|
| Cohort 5(Exon19del/Exon21 L858R NSCLC, 1L, Previously Untreated): Amivantamab (Q4W) + Lazertinib | Experimental | Participants with treatment-naïve locally advanced or metastatic NSCLC harboring an EGFR Exon19del or Exon 21 L858R mutation will receive amivantamab SC-CF induction with 1,600 mg (or 2,240 mg if BW >=80 kg) on Cycle 1 Days 1, 8, 15, and 22, starting with Cycle 2 on Day 1 of each next 28-day cycle, amivantamab SC-CF (160 mg/mL co-formulated with rHuPH20) by manual injection at 3,520 mg (or 4,640 mg if BW >=80 kg); along with lazertinib 240 mg by mouth once daily from Cycle 1 Day 1. Eligible participants will be given an option to enter LTE phase and may continue to receive access to study treatment(s) within the study by transferring to the DA-LTE Phase. |
|
| Cohort6(Exon19del/Exon21L858R,NSCLC1L,PreviouslyUntreated):Amivantamab(Q2W)+Lazertinib+Anticoagulant | Experimental | Participants with treatment-naive locally advanced or metastatic NSCLC harboring an EGFR Exon19del or Exon 21 L858R mutation treated will receive will receive amivantamab SC-CF injection, 1600 milligrams (mg) and 2240 mg if body weight is greater than or equal to (>=) 80 kilograms (kg), on Cycle 1 Days 1, 8, 15, and 22 and on Days 1 and 15 of each subsequent 28-day cycle, starting with Cycle 2, along with lazertinib 240 mg orally once daily from Cycle 1 Day 1. Participants will additionally take prophylactic anticoagulation with a direct oral anticoagulant (DOAC) or a low molecular weight heparin (LMWH) for the first four months of study treatment (from Day 1 through Day 120) with the combination of amivantamab and lazertinib. Eligible participants will be given an option to enter LTE phase and may continue to receive access to study treatment(s) within the study by transferring to the DA-LTE Phase. |
|
| Cohort 7(Exon19del/Exon21 L858R NSCLC,2L,Post Amivantamab+Lazertinib):Amivantamab(Q3W)+Chemotherapy | Experimental | Participants with locally advanced or metastatic NSCLC harboring an EGFR exon19del or exon 21 L858R mutation who have experienced disease progression on or after the combination of amivantamab and lazertinib will receive amivantamab SC-CF injection 1600 mg or 2240 mg if body weight is >=80 kg on Cycle 1 Day 1, 2400 mg or 3360 mg if body weight is >=80 kg on Cycle 1 Day 8 and 15 and on Day 1 of each subsequent 21-day cycle starting with Cycle 2; in combination with IV infusion carboplatin area under the concentration-time curve 5 mg/mL per minute (AUC 5) maximum 750 mg on Day 1 of each 21-day cycle, for up to 4 cycles; and pemetrexed 500 mg/m^2 as an IV infusion (with vitamin supplementation) on Day 1 of each 21-day until disease progression. Eligible participants will be given an option to enter LTE phase and may continue to receive access to study treatment(s) within the study by transferring to the DA-LTE Phase. |
|
|
| Lazertinib | Drug | Lazertinib will be administered as an oral tablet. |
|
|
| Carboplatin | Drug | Carboplatin will be administrated by IV infusion. |
|
| Pemetrexed | Drug | Pemetrexed will be administered by IV infusion. |
|
| Direct Oral Anticoagulant (DOAC) | Drug | DOAC will be administered orally. |
|
| Low Molecular Weight Heparin (LMWH) | Drug | LMWH will be administered subcutaneously. |
|
| Up to approximately 4 years and 9 months |
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. Severity of AEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event. |
| Up to 1 year 6 months |
| All Cohorts Except Cohort 4: Number of Participants with Abnormalities in Clinical Laboratory Values | Number of participants with abnormalities in clinical laboratory values (which includes serum chemistry, hematology, coagulation, urinalysis, and serology) will be reported. | Up to 1 year 6 months |
| All Cohorts Except Cohort 4: Number of Participants with Abnormalities in Clinical Laboratory Values by Severity | Number of participants with abnormalities in clinical laboratory values which includes serum chemistry, hematology, coagulation, urinalysis, and serology) by severity will be reported. Severity of laboratory values abnormalities will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event. | Up to 1 year 6 months |
| All Cohorts Except Cohort 4: ORR Based on Independent Central Review (ICR) | ORR based on ICR will be reported. The ORR is defined as the percentage of participants who achieve a CR or PR, based on RECIST version 1.1, as confirmed by ICR. | Up to 1 year 6 months |
| All Cohorts Except Cohort 4: Duration of Response (DoR) Based on Investigator Assessment (INV) | DoR based on INV is defined as the time from the date of first documented response (PR or CR) until the date of documented progression or death, whichever comes first, for participants who have PR or CR. | Up to 1 year 6 months |
| All Cohorts Except Cohort 4: Time to Response (TTR) Based on INV | TTR (that is, time to first response) based on INV is defined as the time from the first dose of study treatment to the date of first documentation of a response (PR or CR) prior to any disease progression and subsequent anticancer therapy, based on RECIST version 1.1., for participants who have PR or CR as their best response. | Up to 1 year 6 months |
| All Cohorts Except Cohort 4: Clinical Benefit Rate (CBR) | CBR is defined as the percentage of participants achieving CR or PR, or durable standard deviation (SD) of a duration of at least 11 weeks as defined by RECIST version 1.1. | Up to 1 year 6 months |
| All Cohorts Except Cohort 4: Progression-free Survival (PFS) | The PFS is defined as the time from the first dose of study treatment until the date of objective disease progression or death, whichever comes first, based on RECIST version 1.1. | Up to 3 years |
| All Cohorts Except Cohort 4: Overall Survival (OS) | The OS is defined as the time from the first dose of study treatment until the date of death due to any cause. | Up to approximately 4 years |
| All Cohorts Except Cohort 4: Number of Participants with Venous Thromboembolic Events (VTE) | Number of participants with adverse events of VTE (pulmonary embolism and deep vein thrombosis) will be reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. | Up to 1 year 6 months |
| All Cohorts Except Cohort 4: Number of Participants with Venous Thromboembolic Events (VTE) by Severity | Number of participants with adverse events of VTE (pulmonary embolism and deep vein thrombosis) by severity will be reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. Severity of AEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). | Up to 1 year 6 months |
| All Cohorts Except Cohort 4: Serum Concentration Immediately Prior to the Next Dose Administration (Ctrough) of Amivantamab | Ctrough is defined as the serum concentration of amivantamab immediately prior to the next drug administration. | Cycle 2 Day 1 of 28-day cycle |
| Cohort 4: Cancer Therapy Satisfaction as Assessed by Modified Therapy Administration Satisfaction Questionnaire - Intravenous (TASQ-IV) | Patient-reported outcome (PRO): Cancer therapy satisfaction will be assessed using the modified TASQ-IV. The modified TASQ is a 12-item questionnaire measuring the impact of each mode of treatment administration on five domains: physical impact, psychological impact, impact on activities of daily living, convenience, and satisfaction. Each of the domain/scale scores is scored on a 1-100 scale, where 0 is worst and 100 is best. | Up to 1 year 6 months |
| Cohort 4: Cancer Therapy Satisfaction as Assessed by Modified Therapy Administration Satisfaction Questionnaire - Subcutaneous (TASQ-SC) | PRO: Cancer therapy satisfaction will be assessed using the modified TASQ-SC. The modified TASQ is a 12-item questionnaire measuring the impact of each mode of treatment administration on five domains: physical impact, psychological impact, impact on activities of daily living, convenience, and satisfaction. Each of the domain/scale scores is scored on a 1-100 scale, where 0 is worst and 100 is best. | Up to 1 year 6 months |
| Cohort 4: Patient-reported Status as Assessed by Patient Global Impression of Change (PGIC) Scale Score | Patient-reported status as assessed by PGIC scale score will be reported. The PGIC is an assessment of the participant's overall sense of whether there has been a change since starting treatment. The PGIC is a 7-point response scale. Participants will be asked to rate their current fatigue as compared to when they started the study, using the following 7-point scale: 1 = Much better, 2 = Moderately better, 3 = A little better, 4 = No change, 5 = A little worse, 6 = Moderately worse, and 7 = Much worse. | Up to 1 year 6 months |
| Cohort 4: Patient-reported Status as Assessed by Patient Global Impression of Symptom Severity (PGIS) Scale Score | Patient-reported status as assessed by PGIS scale score will be reported. The PGIS is an assessment of lung cancer severity at a given point in time. The PGIS is a 5-point response scale. Participants will be asked to rate their fatigue over the past 7 days using the following 5-point scale: 1 = None, 2 = Mild, 3 = Moderate, 4 = Severe, and 5 = Very severe. | Up to 1 year 6 months |
| University of California Irvine |
| Recruiting |
| Orange |
| California |
| 92868 |
| United States |
| Stanford Cancer Institute | Recruiting | Stanford | California | 94305 | United States |
| Johns Hopkins Office of Capital Region Research - Sibley Memorial Hospital | Recruiting | Washington D.C. | District of Columbia | 20016 | United States |
| Baptist Lynn Cancer Institute | Completed | Boca Raton | Florida | 33486 | United States |
| Mount Sinai Medical Center | Recruiting | Miami Beach | Florida | 33140 | United States |
| AdventHealth | Recruiting | Orlando | Florida | 32804 | United States |
| H. Lee Moffitt Cancer & Research Institute | Completed | Tampa | Florida | 33612 | United States |
| University of Kansas Cancer Center | Recruiting | Westwood | Kansas | 66205 | United States |
| Sidney Kimmel Cancer Center - Bayview Campus | Recruiting | Baltimore | Maryland | 21224 | United States |
| Boston Medical Center | Recruiting | Boston | Massachusetts | 02118 | United States |
| Washington University School Of Medicine | Recruiting | St Louis | Missouri | 63110 | United States |
| Hackensack University Medical Center | Recruiting | Hackensack | New Jersey | 07601 | United States |
| Rutgers Cancer Institute of New Jersey | Recruiting | New Brunswick | New Jersey | 08901 | United States |
| Hematology-Oncology Associates of CNY | Completed | East Syracuse | New York | 13057 | United States |
| Novant Health 1 | Completed | Charlotte | North Carolina | 28204 | United States |
| Novant Health | Completed | Winston-Salem | North Carolina | 27106 | United States |
| Cleveland Clinic 1 | Completed | Cleveland | Ohio | 44111 | United States |
| Cleveland Clinic | Completed | Cleveland | Ohio | 44195 | United States |
| Cleveland Clinic 2 | Completed | Mayfield Heights | Ohio | 44124 | United States |
| Cleveland Clinic 3 | Completed | Warrensville Heights | Ohio | 44122 | United States |
| The Huntsman Cancer Institute | Completed | Salt Lake City | Utah | 84112 | United States |
| Virginia Cancer Specialists | Recruiting | Fairfax | Virginia | 22031 | United States |
| Providence Regional Cancer Partnership | Completed | Everett | Washington | 98201 | United States |
| Virginia Mason Medical Center | Completed | Seattle | Washington | 98101 | United States |
| Swedish Cancer Institute | Recruiting | Seattle | Washington | 98104 | United States |
| Fundacao Pio XII | Recruiting | Barretos | 14784-400 | Brazil |
| PERSONAL Oncologia de Precisao e Personalizada | Recruiting | Belo Horizonte | 30130 090 | Brazil |
| Instituto do Cancer de Londrina Hospital do Cancer de Londrina | Recruiting | Londrina | 86015 | Brazil |
| Associacao Hospitalar Moinhos de Vento | Recruiting | Porto Alegre | 90035-001 | Brazil |
| Instituto D Or de Pesquisa e Ensino IDOR | Recruiting | Rio de Janeiro | 22281 100 | Brazil |
| Instituto D Or de Pesquisa e Ensino IDOR 1 | Recruiting | Salvador | 41253-190 | Brazil |
| Hospital Alemao Oswaldo Cruz | Recruiting | São Paulo | 01327 001 | Brazil |
| Impar Servicos Hospitalares SA Hospital Nove de Julho | Completed | São Paulo | 01409-001 | Brazil |
| Fundacao Antonio Prudente A C Camargo Cancer Center | Recruiting | São Paulo | 01509 900 | Brazil |
| Affiliated Hospital of Hebei University | Completed | Baoding | 071051 | China |
| Jilin cancer hospital | Recruiting | Changchun | 130000 | China |
| Sichuan Cancer Hospital | Recruiting | Chengdu | 610041 | China |
| West China Hospital Sichuan University | Recruiting | Chengdu | 610047 | China |
| The First Affiliated Hospital of PLA Army Medical University | Recruiting | Chongqing | 400038 | China |
| The First Affiliated Hospital Sun Yat sen University | Recruiting | Guangzhou | 510060 | China |
| The First Affiliated Hospital Zhejiang University College of Medicine | Recruiting | Hangzhou | 310003 | China |
| Sir Run Run Shaw Hospital Zhejiang University School of Medicine | Recruiting | Hangzhou | 310016 | China |
| Harbin medical university cancer hospital | Recruiting | Harbin | 150000 | China |
| Huizhou Municipal Central Hospital | Recruiting | Huizhou | 516001 | China |
| Liuzhou people's Hospital | Completed | Liuzhou | 545006 | China |
| Fudan University Shanghai Cancer Center | Recruiting | Shanghai | 200032 | China |
| Tianjin Medical University General Hospital | Recruiting | Tianjin | 300052 | China |
| The First Affiliated Hospital of Wenzhou Medical University | Recruiting | Wenzhou | 325000 | China |
| Union Hospital Tongji Medical College of Huazhong University of Science and Technology | Recruiting | Wuhan | 430022 | China |
| Hospital of Jiangnan University | Completed | Wuxi | 214122 | China |
| The First Affiliated Hospital of Xian Jiaotong University | Recruiting | Xi'an | 710061 | China |
| Yantai Yuhuangding Hospital | Completed | Yantai | 264000 | China |
| Centre Francois Baclesse | Recruiting | Caen | 14076 | France |
| Centre Georges-François Leclerc | Completed | Dijon | 21079 | France |
| Institut de Cancérologie du Gard | Recruiting | Nîmes | 30029 | France |
| Institut Curie | Recruiting | Paris | 75248 | France |
| Institut de cancerologie de l'ouest | Recruiting | Saint-Herblain | 44805 | France |
| Gustave Roussy | Recruiting | Villejuif | 94800 | France |
| Evangelische Lungenklinik Berlin | Completed | Berlin | 13125 | Germany |
| Universitaetsklinikum Koeln | Recruiting | Cologne | 50937 | Germany |
| LungenClinic Grosshansdorf GmbH | Recruiting | Grosshandorf | 22927 | Germany |
| Lungenfachklinik Immenhausen | Recruiting | Immenhausen | 34376 | Germany |
| Klinikum Würzburg Mitte gGmbH Standort Missioklinik | Recruiting | Würzburg | 97074 | Germany |
| Rambam Medical Center | Recruiting | Haifa | 3109601 | Israel |
| Shaare Zedek Medical Center | Recruiting | Jerusalem | 9103102 | Israel |
| Meir Medical Center | Completed | Kfar Saba | 44281 | Israel |
| Rabin Medical Center | Recruiting | Petah Tikva | 4941492 | Israel |
| Sheba Medical Center | Recruiting | Ramat Gan | 52621 | Israel |
| Policlinico Hospital San Martino- IRCCS for Oncology | Recruiting | Genova | 16132 | Italy |
| Ospedale San Raffaele | Recruiting | Milan | 20132 | Italy |
| ASST Grande Ospedale Metropolitano Niguarda | Recruiting | Milan | 20162 | Italy |
| Azienda Ospedaliera San Gerardo | Recruiting | Monza | 20090 | Italy |
| Azienda Ospedaliera Specialistica dei Colli | Recruiting | Naples | 80131 | Italy |
| National Hospital Organization Himeji Medical Center | Active, not recruiting | Himeji | 670-8520 | Japan |
| Saiseikai Matsusaka Municipal Hospital | Active, not recruiting | Matsusaka | 515 8544 | Japan |
| Niigata Cancer Center Hospital | Active, not recruiting | Niigata | 951-8566 | Japan |
| Shizuoka Cancer Center | Active, not recruiting | Shizuoka | 411 8777 | Japan |
| The Cancer Institute Hospital of JFCR | Active, not recruiting | Tokyo | 135 8550 | Japan |
| Wakayama Medical University Hospital | Active, not recruiting | Wakayama | 641 8510 | Japan |
| University Malaya Medical Centre | Recruiting | Kuala Lumpur | 59100 | Malaysia |
| Hospital Tengku Ampuan Afzan | Recruiting | Kuantan | 25100 | Malaysia |
| Hospital Umum Sarawak | Recruiting | Kuching | 93586 | Malaysia |
| Beacon Hospital Sdn Bhd | Recruiting | Petaling Jaya | 46050 | Malaysia |
| National Cancer Center | Recruiting | Goyang-si | 10408 | South Korea |
| Seoul National University Bundang Hospital | Recruiting | Seongnam-si | 13620 | South Korea |
| Seoul National University Hospital | Recruiting | Seoul | 03080 | South Korea |
| Severance Hospital Yonsei University Health System | Recruiting | Seoul | 03722 | South Korea |
| Asan Medical Center | Completed | Seoul | 05505 | South Korea |
| Hosp Univ A Coruna | Recruiting | A Coruña | 15006 | Spain |
| General University Hospital of Alicantet | Recruiting | Alicante | 03010 | Spain |
| Hosp. Del Mar | Recruiting | Barcelona | 08003 | Spain |
| Hosp. de La Santa Creu I Sant Pau | Recruiting | Barcelona | 08025 | Spain |
| Hosp Univ Vall D Hebron | Recruiting | Barcelona | 08035 | Spain |
| Inst. Cat. Doncologia-H Duran I Reynals | Recruiting | Barcelona | 8908 | Spain |
| Hosp. Gral. Univ. Gregorio Maranon | Recruiting | Madrid | 28007 | Spain |
| Hosp. Univ. Ramon Y Cajal | Recruiting | Madrid | 28034 | Spain |
| Hosp. Univ. 12 de Octubre | Recruiting | Madrid | 28041 | Spain |
| Hosp. Univ. La Paz | Recruiting | Madrid | 28046 | Spain |
| Hosp Regional Univ de Malaga | Recruiting | Málaga | 29010 | Spain |
| Hosp. Virgen Macarena | Recruiting | Seville | 41009 | Spain |
| Hosp. Clinico Univ. de Valencia | Recruiting | Valencia | 46010 | Spain |
| Hosp. Gral. Univ. Valencia | Recruiting | Valencia | 46014 | Spain |
| Cheltenham General Hospital | Completed | Cheltenham | GL53 7AN | United Kingdom |
| Torbay Hospital-Devon | Recruiting | Devon | TQ2 7AA | United Kingdom |
| Edinburgh Cancer Centre Western General | Recruiting | Edinburgh | EH4 2XU | United Kingdom |
| Leicester Royal Infirmary | Recruiting | Leicester | LE1 5WW | United Kingdom |
| University College London Hospitals | Recruiting | London | NW1 2PG | United Kingdom |
| Nottingham City Hospital | Recruiting | Nottingham | NG5 1PB | United Kingdom |
| Queen Alexandra Hospital | Recruiting | Portsmouth | PO6 3LY | United Kingdom |
| ID | Term |
|---|---|
| D002289 | Carcinoma, Non-Small-Cell Lung |
| ID | Term |
|---|---|
| D002283 | Carcinoma, Bronchogenic |
| D001984 | Bronchial Neoplasms |
| D008175 | Lung Neoplasms |
| D012142 | Respiratory Tract Neoplasms |
| D013899 | Thoracic Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C000718215 | amivantamab |
| C000707992 | lazertinib |
| D016190 | Carboplatin |
| D000068437 | Pemetrexed |
| C065145 | N(4)-oleylcytosine arabinoside |
| D006495 | Heparin, Low-Molecular-Weight |
| ID | Term |
|---|---|
| D056831 | Coordination Complexes |
| D009930 | Organic Chemicals |
| D006147 | Guanine |
| D007042 | Hypoxanthines |
| D011688 | Purinones |
| D011687 | Purines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
| D005971 | Glutamates |
| D024342 | Amino Acids, Acidic |
| D000596 | Amino Acids |
| D000602 | Amino Acids, Peptides, and Proteins |
| D000600 | Amino Acids, Dicarboxylic |
| D006493 | Heparin |
| D006025 | Glycosaminoglycans |
| D011134 | Polysaccharides |
| D002241 | Carbohydrates |
Not provided
Not provided